Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Perrigo Company has agreed to market the authorized generic version of Astellas U.S. LLC's' Protopic Ointment 0.1% and 0.03%. Shipments to our pharmacy customers have commenced.
Subscribe to our email newsletter
Protopic Ointment (tacrolimus) is indicated to treat moderate to severe eczema. Brand sales were approximately $176 million over the last 52 weeks according to Symphony Health Solutions.
Perrigo’s Chairman, President and CEO Joseph C. Papa stated, "This product was the result of the continued hard work and dedication of Perrigo’s Rx and Astellas’ teams.
"This launch is another example of Perrigo’s investment and commitment to making quality healthcare more affordable for all consumers across the globe."
From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland, has grown to become a leading global healthcare supplier.
Perrigo develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products and active pharmaceutical ingredients (API), and receives royalties from Multiple Sclerosis drug Tysabri.
The Company is the world’s largest manufacturer of OTC healthcare products for the store brand market and an industry leader in pharmaceutical technologies.
Perrigo’s mission is to offer uncompromised "Quality Affordable Healthcare Products" and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as more than 40 other key markets worldwide, including Canada, China and Latin America.